{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:15:04Z","timestamp":1787598904639,"version":"build-2736575974"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012669","name":"Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission","doi-asserted-by":"publisher","award":["No. CSTB2024NSCQ-MSX1265"],"award-info":[{"award-number":["No. CSTB2024NSCQ-MSX1265"]}],"id":[{"id":"10.13039\/501100012669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-03980-2","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T09:44:44Z","timestamp":1747043084000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A network meta-analysis of different interventional treatment strategies for unresectable hepatocellular carcinoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Xing-Yan","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Bang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sui-Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"3980_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3980_CR2","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3322\/caac.21838","volume":"74","author":"N Jokhadze","year":"2024","unstructured":"Jokhadze N, Das A, Dizon DS. Global cancer statistics: a healthy population relies on population health. CA Cancer J Clin. 2024;74:224\u20136.","journal-title":"CA Cancer J Clin"},{"key":"3980_CR3","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1097\/CM9.0000000000002034","volume":"135","author":"H Zhao","year":"2022","unstructured":"Zhao H, Tsauo J, Zhang X, Ma H, Weng N, Yang Z, et al. Prevalence and prognostic impact of hepatopulmonary syndrome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective cohort study. Chin Med J. 2022;135:2043\u20138.","journal-title":"Chin Med J"},{"key":"3980_CR4","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1200\/JCO.2012.44.5643","volume":"31","author":"S Qin","year":"2013","unstructured":"Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil\/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from asia. JCO. 2013;31:3501\u20138.","journal-title":"JCO"},{"key":"3980_CR5","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/ueg2.12286","volume":"10","author":"S Sidali","year":"2022","unstructured":"Sidali S, Tr\u00e9po E, Sutter O, Nault J. New concepts in the treatment of hepatocellular carcinoma. UEG J. 2022;10:765\u201374.","journal-title":"UEG J"},{"key":"3980_CR6","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1159\/000509424","volume":"9","author":"J Zhou","year":"2020","unstructured":"Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition). Liver Cancer. 2020;9:682\u2013720.","journal-title":"Liver Cancer"},{"key":"3980_CR7","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1007\/s12094-024-03498-1","volume":"26","author":"Q Xie","year":"2024","unstructured":"Xie Q, Yang Y, Hao W, Luo C. Unleashing the potential: transarterial chemoembolization combined with intra-arterial infusion of bevacizumab for unresectable hepatocellular carcinoma. Clin Transl Oncol. 2024;26:3075\u201384.","journal-title":"Clin Transl Oncol"},{"key":"3980_CR8","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Monta\u00f1a X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734\u20139.","journal-title":"Lancet"},{"key":"3980_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1053\/j.gastro.2006.05.021","volume":"131","author":"K Takayasu","year":"2006","unstructured":"Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131:461\u20139.","journal-title":"Gastroenterology"},{"key":"3980_CR10","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.7150\/thno.80213","volume":"13","author":"D Wang","year":"2023","unstructured":"Wang D, Rao W. Bench-to-bedside development of multifunctional flexible embolic agents. Theranostics. 2023;13:2114\u201339.","journal-title":"Theranostics"},{"key":"3980_CR11","doi-asserted-by":"publisher","first-page":"13051","DOI":"10.3390\/ijms222313051","volume":"22","author":"C Ebeling Barbier","year":"2021","unstructured":"Ebeling Barbier C, Heindryckx F, Lennern\u00e4s H. Limitations and possibilities of transarterial chemotherapeutic treatment of hepatocellular carcinoma. IJMS. 2021;22:13051.","journal-title":"IJMS"},{"key":"3980_CR12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1148\/radiol.211545","volume":"303","author":"K Zheng","year":"2022","unstructured":"Zheng K, Zhu X, Fu S, Cao G, Li W-Q, Xu L, et al. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: a randomized trial. Radiology. 2022;303:455\u201364.","journal-title":"Radiology"},{"key":"3980_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1159\/000524893","volume":"11","author":"K Ueshima","year":"2022","unstructured":"Ueshima K, Komemushi A, Aramaki T, Iwamoto H, Obi S, Sato Y, et al. Clinical practice guidelines for hepatic arterial infusion chemotherapy with a port system proposed by the Japanese society of interventional radiology and Japanese society of implantable port assisted treatment. Liver Cancer. 2022;11:407\u201325.","journal-title":"Liver Cancer"},{"key":"3980_CR14","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3350\/cmh.2022.0391","volume":"29","author":"H Iwamoto","year":"2023","unstructured":"Iwamoto H, Shimose S, Shirono T, Niizeki T, Kawaguchi T. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity. Clin Mol Hepatol. 2023;29:593\u2013604.","journal-title":"Clin Mol Hepatol"},{"key":"3980_CR15","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00535-014-0978-3","volume":"50","author":"DS Song","year":"2015","unstructured":"Song DS, Song MJ, Bae SH, Chung WJ, Jang JY, Kim YS, et al. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol. 2015;50:445\u201354.","journal-title":"J Gastroenterol"},{"key":"3980_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3892\/etm.2011.237","volume":"2","author":"Y HIRAMINE","year":"2011","unstructured":"HIRAMINE Y, UTO H, IMAMURA Y, TABU K, BABA Y, HIWAKI T, et al. Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: a comparative study. Exp Ther Med. 2011;2:433\u201341.","journal-title":"Exp Ther Med"},{"key":"3980_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1743-7563.2012.01543.x","volume":"8","author":"SW JEONG","year":"2012","unstructured":"JEONG SW, JANG JY, LEE JE, LEE SH, KIM SG, CHA S-W, et al. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma. Asia Pac J Clin Oncol. 2012;8:164\u201371.","journal-title":"Asia Pac J Clin Oncol"},{"key":"3980_CR18","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/cam4.476","volume":"4","author":"K Fukubayashi","year":"2015","unstructured":"Fukubayashi K, Tanaka M, Izumi K, Watanabe T, Fujie S, Kawasaki T, et al. Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method. Cancer Med. 2015;4:1214\u201323.","journal-title":"Cancer Med"},{"key":"3980_CR19","doi-asserted-by":"publisher","first-page":"102313","DOI":"10.1016\/j.clinre.2024.102313","volume":"48","author":"J Ji","year":"2024","unstructured":"Ji J, Zhang Z, Hou Z, Qiu G, Mi S, Jin Z, et al. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC): a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2024;48:102313.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"3980_CR20","doi-asserted-by":"publisher","first-page":"e2126992","DOI":"10.1001\/jamanetworkopen.2021.26992","volume":"4","author":"YJ Zhang","year":"2021","unstructured":"Zhang YJ, Chen MS, Chen Y, Lau WY, Peng Z. Long-term outcomes of transcatheter arterial chemoembolization combined with radiofrequency ablation as an initial treatment for early-stage hepatocellular carcinoma. JAMA Netw Open. 2021;4:e2126992.","journal-title":"JAMA Netw Open"},{"key":"3980_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000521227","volume":"11","author":"J Jung","year":"2022","unstructured":"Jung J, Joo JH, Kim SY, Kim JH, Choi J, Lee D, et al. Radiologic response as a prognostic factor in advanced hepatocellular carcinoma with macroscopic vascular invasion after transarterial chemoembolization and radiotherapy. Liver Cancer. 2022;11:152\u201361.","journal-title":"Liver Cancer"},{"key":"3980_CR22","doi-asserted-by":"publisher","first-page":"797349","DOI":"10.3389\/fonc.2022.797349","volume":"12","author":"Y-B Wang","year":"2022","unstructured":"Wang Y-B, Ma R, Wang Z-B, Shi Q-L, Zhang L, Chen W-Z, et al. Transcatheter arterial chemoembolization in combination with high-intensity focused ultrasound for intermediate and advanced hepatocellular carcinoma: a meta-analysis. Front Oncol. 2022;12:797349.","journal-title":"Front Oncol"},{"key":"3980_CR23","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.3350\/cmh.2023.0131","volume":"29","author":"HI Kim","year":"2023","unstructured":"Kim HI, An J, Han S, Shim JH. Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis. Clin Mol Hepatol. 2023;29:1013\u201328.","journal-title":"Clin Mol Hepatol"},{"key":"3980_CR24","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaoncol.2015.2189","volume":"1","author":"YR Huo","year":"2015","unstructured":"Huo YR, Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma. JAMA Oncol. 2015;1:756.","journal-title":"JAMA Oncol"},{"key":"3980_CR25","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"3980_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"3980_CR27","doi-asserted-by":"publisher","first-page":"052","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet J, Modified. RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:052\u201360.","journal-title":"Semin Liver Dis"},{"key":"3980_CR28","doi-asserted-by":"publisher","first-page":"259","DOI":"10.29271\/jcpsp.2020.03.259","volume":"30","author":"J Feng","year":"2020","unstructured":"Feng J, Yang J, Li J, Jin X, Sun Q. Transcatheter arterial chemoembolisation combined with radiofrequency ablation on hepatocellular carcinoma and levels of relevant markers. J Coll Physicians Surg Pak. 2020;30:259\u201362.","journal-title":"J Coll Physicians Surg Pak"},{"key":"3980_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3233\/CBM-160508","volume":"20","author":"FQ Jiang","year":"2017","unstructured":"Jiang FQ, Lu W, Yang C, Du P, Ma JP, Yang J, et al. Curative effect of transcatheter arterial chemoembolization combined with radiofrequency ablation in treating hepatic cell carcinoma and its effect on serum markers. CBM. 2017;20:17\u201322.","journal-title":"CBM"},{"issue":"09","key":"3980_CR30","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.13241\/j.cnki.pmb.2021.09.015","volume":"21","author":"J Liu","year":"2021","unstructured":"Liu J, Li F, Wang NF, et al. Effect of transcatheter arterial chemoembolization combined with radiofrequency ablation on survival rate, liver function and T lymphocyte subsets in patients with middle and advanced stage liver cancer. Progress Mod Biomed. 2021;21(09):1669\u201372. https:\/\/doi.org\/10.13241\/j.cnki.pmb.2021.09.015","journal-title":"Progress Mod Biomed"},{"issue":"09","key":"3980_CR31","first-page":"1375","volume":"30","author":"JS Wen","year":"2015","unstructured":"Wen JS, Li CY, Wu ZQ, et al. The efficacy and safety of transcatheter arterial chemoembolization combined with radiofrequency ablation for hepatocellular carcinoma. J Practical Cancer. 2015;30(09):1375\u20138.","journal-title":"J Practical Cancer"},{"issue":"01","key":"3980_CR32","first-page":"1","volume":"30","author":"PL Zhu","year":"2018","unstructured":"Zhu PL, Wang DS, Tian DF. Investigation on transcatheter artery chemoembolization combined with radiofrequency ablation for treatment of primary hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2018;30(01):1\u20134.","journal-title":"J Hepatobiliary Pancreat Surg"},{"issue":"03","key":"3980_CR33","first-page":"353","volume":"40","author":"YM Li","year":"2021","unstructured":"Li YM, Wang LL, Zhou Y. Study on the efficacy and safety of TACE combined with RFA in the treatment of primary hepatocellular carcinoma with different BCLC stages. J Southeast Univ (Medical Sci Edition). 2021;40(03):353\u20139.","journal-title":"J Southeast Univ (Medical Sci Edition)"},{"issue":"05","key":"3980_CR34","first-page":"379","volume":"5","author":"XC Jiang","year":"2015","unstructured":"Jiang XC, Cui HX, Zhang J, et al. Effects of TACE combined with RFA for hepatocellular carcinoma and prognostic factors analysis. J Tumor Pharmacol. 2015;5(05):379\u201383.","journal-title":"J Tumor Pharmacol"},{"issue":"22","key":"3980_CR35","first-page":"3597","volume":"26","author":"HZ Wang","year":"2018","unstructured":"Wang HZ, Chen HN, Song TM. Effect of radiofrequency ablation combined with transcatheter arterial chemoembolization on gene expression and survival of primary hepatocellular carcinoma. Mod Tumor Med. 2018;26(22):3597\u2013601.","journal-title":"Mod Tumor Med"},{"issue":"11","key":"3980_CR36","first-page":"65","volume":"16","author":"JX Li","year":"2021","unstructured":"Li JX. Clinical efficacy of hepatic artery chemoembolization combined with radiofrequency ablation in the treatment of patients with advanced liver cancer. Chin J Drug Econ. 2021;16(11):65\u20138.","journal-title":"Chin J Drug Econ"},{"key":"3980_CR37","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3109\/02656736.2011.605099","volume":"27","author":"C Liu","year":"2011","unstructured":"Liu C, Liang P, Liu F, Wang Y, Li X, Han Z, et al. MWA combined with TACE as a combined therapy for unresectable large-sized hepatocellular carcinoma. Int J Hyperth. 2011;27:654\u201362.","journal-title":"Int J Hyperth"},{"key":"3980_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.4103\/0973-1482.200598","volume":"12","author":"P Yang","year":"2016","unstructured":"Yang P, Li W, Man W, Guo H. Clinical study of transcatheter arterial chemoembolization combined with microwave ablation in the treatment of advanced hepatocellular carcinoma. J Cancer Res Therapy. 2016;12:217.","journal-title":"J Cancer Res Therapy"},{"issue":"05","key":"3980_CR39","doi-asserted-by":"publisher","first-page":"431","DOI":"10.14000\/j.cnki.issn.1008-1704.2017.05.019","volume":"22","author":"HX Zhang","year":"2017","unstructured":"Zhang HX, Ma XM, Fu QJ, et al. Efficacy and prognostic analysis of sequential treatment for advanced hepatocellular carcinoma with hepatic artery chemoembolization combined with percutaneous microwave ablation. Liver. 2017;22(05):431\u20134. https:\/\/doi.org\/10.14000\/j.cnki.issn.1008-1704.2017.05.019","journal-title":"Liver"},{"issue":"02","key":"3980_CR40","first-page":"212","volume":"44","author":"SF Liu","year":"2020","unstructured":"Liu SF, Zhong YJ, Peng HY. Efficacy observation of hepatic artery chemoembolization (TACE) combined with ultrasound-guided microwave ablation for treating hepatocellular carcinoma at special locations. Guizhou Med J. 2020;44(02):212\u20134.","journal-title":"Guizhou Med J"},{"issue":"03","key":"3980_CR41","first-page":"554","volume":"38","author":"JP Liu","year":"2018","unstructured":"Liu JP, Xiong Y, Fan YG, et al. The impact of microwave ablation combined with hepatic artery chemoembolization on immune function, AFP levels, and survival time in hepatocellular carcinoma patients. Chin J Gerontol. 2018;38(03):554\u20136.","journal-title":"Chin J Gerontol"},{"issue":"03","key":"3980_CR42","first-page":"191","volume":"30","author":"JL An","year":"2018","unstructured":"An JL, Han XY, Sha JF, et al. Clinical study of transcatheter arterial chemoembolization sequentially combined with microwave ablation in the treatment of single primary hepatocellular carcinoma with diameter greater than 5\u00a0cm. J Hepatobiliary Pancreat Surg. 2018;30(03):191\u20136.","journal-title":"J Hepatobiliary Pancreat Surg"},{"issue":"07","key":"3980_CR43","first-page":"62","volume":"29","author":"JW Ma","year":"2022","unstructured":"Ma JW. Study on the safety and efficacy of TACE combined with microwave ablation in the treatment of unresectable solitary liver cancer. J Rare Dis. 2022;29(07):62\u20134.","journal-title":"J Rare Dis"},{"issue":"03","key":"3980_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.13764\/j.cnki.lcsy.2022.03.010","volume":"23","author":"Q Wang","year":"2022","unstructured":"Wang Q. Clinical efficacy of ultrasound-guided microwave ablation combined with tace in the treatment of primary liver cancer. J Practical Clin Med. 2022;23(03):32\u20134. https:\/\/doi.org\/10.13764\/j.cnki.lcsy.2022.03.010","journal-title":"J Practical Clin Med"},{"key":"3980_CR45","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/j.ejca.2010.06.015","volume":"46","author":"C Li","year":"2010","unstructured":"Li C, Zhang W, Zhang R, Zhang L, Wu P, Zhang F. Therapeutic effects and prognostic factors in high-intensity focused ultrasound combined with chemoembolisation for larger hepatocellular carcinoma. Eur J Cancer. 2010;46:2513\u201321.","journal-title":"Eur J Cancer"},{"key":"3980_CR46","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1148\/radiol.2352030916","volume":"235","author":"J Hu","year":"2005","unstructured":"Hu J, Bao Q, Cao G, Zhu X, Yang R, Ji X, et al. Advanced hepatocellular carcinoma: treatment with high-intensity focused ultrasound ablation combined with transcatheter arterial embolization. Radiology. 2005;235:659\u201367.","journal-title":"Radiology"},{"key":"3980_CR47","doi-asserted-by":"publisher","first-page":"414","DOI":"10.29271\/jcpsp.2019.05.414","volume":"29","author":"Y Luo","year":"2019","unstructured":"Luo Y, Jiang Y. Comparison of efficiency of TACE plus HIFU and TACE alone on patients with primary liver cancer. J Coll Physicians Surg Pak. 2019;29:414\u20137.","journal-title":"J Coll Physicians Surg Pak"},{"issue":"04","key":"3980_CR48","first-page":"496","volume":"15","author":"WH Dong","year":"2015","unstructured":"Dong WH, Gu JP, Zha MB. Clinical effect of transcatheter arterial chemoembolization in combination with high-intensity focused ultrasound therapy for advanced stage of hepatic carcinoma. J Trop Med. 2015;15(04):496\u20139.","journal-title":"J Trop Med"},{"issue":"11","key":"3980_CR49","first-page":"870","volume":"16","author":"P Li","year":"2013","unstructured":"Li P, Zhou DH, Lv W, et al. Clinical study of TACE in combination with high-intensity focused ultrasound therapy for advanced stage hepatocellular carcinoma. Chin J Mod Developments Gen Surg. 2013;16(11):870\u20134.","journal-title":"Chin J Mod Developments Gen Surg"},{"key":"3980_CR50","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1148\/radiology.197.3.7480761","volume":"197","author":"C Bartolozzi","year":"1995","unstructured":"Bartolozzi C, Lencioni R, Caramella D, Vignali C, Cioni R, Mazzeo S, et al. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology. 1995;197:812\u20138.","journal-title":"Radiology"},{"key":"3980_CR51","doi-asserted-by":"publisher","first-page":"6104","DOI":"10.3748\/wjg.v11.i39.6104","volume":"11","author":"G Becker","year":"2005","unstructured":"Becker G. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol. 2005;11:6104.","journal-title":"World J Gastroenterol"},{"issue":"2 Suppl 6","key":"3980_CR52","first-page":"S6","volume":"24","author":"K Yamamoto","year":"1997","unstructured":"Yamamoto K, Masuzawa M, Kato M, Kurosawa K, Kaneko A, Ishida H, et al. Evaluation of combined therapy with chemoembolization and ethanol injection for advanced hepatocellular carcinoma. Semin Oncol. 1997;24(2 Suppl 6):S6\u201350.","journal-title":"Semin Oncol"},{"key":"3980_CR53","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.1007\/BF00686681","volume":"33","author":"T Kato","year":"1994","unstructured":"Kato T, Saito Y, Niwa M, Ishiguro J, Ogoshi K. Combination therapy of transcatheter chemoembolization and percutaneous ethanol injection therapy for unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol. 1994;33:S115\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"26","key":"3980_CR54","first-page":"63","volume":"49","author":"MH Dai","year":"2009","unstructured":"Dai MH, Xu HW, Liu LP, et al. Hepatic artery chemoembolization combined with absolute ethanol injection for the treatment of advanced hepatocellular carcinoma. Shandong Med J. 2009;49(26):63\u20134.","journal-title":"Shandong Med J"},{"issue":"04","key":"3980_CR55","first-page":"11","volume":"12","author":"Y Ju","year":"2020","unstructured":"Ju Y, Shen ZY. Clinical efficacy of percutaneous ethanol injection combined with transcatheter arterial chemoembolization in treatment of primary liver cancer. Chin J Liver Disease (Electronic Edition). 2020;12(04):11\u20136.","journal-title":"Chin J Liver Disease (Electronic Edition)"},{"key":"3980_CR56","first-page":"5733","volume":"16","author":"Y Liu","year":"2018","unstructured":"Liu Y, Yan J, Wang F. Effects of TACE combined with precise RT on p53 gene expression and prognosis of HCC patients. Oncol Lett. 2018;16:5733\u20138.","journal-title":"Oncol Lett"},{"key":"3980_CR57","doi-asserted-by":"publisher","first-page":"100689","DOI":"10.1016\/j.jhepr.2023.100689","volume":"5","author":"C F\u00e9ray","year":"2023","unstructured":"F\u00e9ray C, Campion L, Mathurin P, Archambreaud I, Mirabel X, Bronowicki JP, et al. TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: a randomised controlled trial. JHEP Rep. 2023;5:100689.","journal-title":"JHEP Rep"},{"issue":"06","key":"3980_CR58","first-page":"681","volume":"29","author":"ZS Zhu","year":"2014","unstructured":"Zhu ZS, Yan WH, Peng X-M, et al. Effect of TACE combined with stereotactic radiotherapy on the prognosis of hepatocellular carcinoma with portal vein thrombosis. J Practical Cancer. 2014;29(06):681\u20133.","journal-title":"J Practical Cancer"},{"issue":"12","key":"3980_CR59","first-page":"134","volume":"12","author":"FE Zhang","year":"2022","unstructured":"Zhang FE. Effect of TACE combined with radiotherapy in the treatment of middle and advanced PHC. Chin Med Sci J. 2022;12(12):134\u20138.","journal-title":"Chin Med Sci J"},{"issue":"11","key":"3980_CR60","first-page":"2489","volume":"35","author":"MY Ma","year":"2019","unstructured":"Ma MY, Lin GY, Cai ZY, et al. Efficacy and safety of microsphere transarterial chemoembolization combined with radiotherapy versus microsphere transarterial chemoembolization alone in treatment of patients with unresectable liver cancer. J Clin Hepatol. 2019;35(11):2489\u201394.","journal-title":"J Clin Hepatol"},{"key":"3980_CR61","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.ijrobp.2024.09.021","volume":"121","author":"Y Chen","year":"2025","unstructured":"Chen Y, Hu Y, Shen J, Du S, Yan J, Zhou L, et al. External beam radiation therapy after transarterial chemoembolization versus transarterial chemoembolization alone for treatment of inoperable hepatocellular carcinoma: a randomized phase 3 trial. Int J Radiat Oncol Biol Phys. 2025;121:414\u201322.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3980_CR62","first-page":"692","volume":"19","author":"W Chen","year":"2014","unstructured":"Chen W, Yuan S, Zhu L, Sun X, Zheng W. Three-dimensional conformal radiotherapy in combination with transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma. J Balkan Union Oncol. 2014;19:692\u20137.","journal-title":"J Balkan Union Oncol"},{"key":"3980_CR63","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1200\/JCO.21.00608","volume":"40","author":"QJ Li","year":"2022","unstructured":"Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial. J Clin Oncol. 2022;40:150\u201360.","journal-title":"J Clin Oncol"},{"issue":"01","key":"3980_CR64","first-page":"21","volume":"13","author":"Z Jiang","year":"2025","unstructured":"Jiang Z, Wen KL, Zha HQ, et al. Comparison of the efficacy and safety of transcatheter arterial chemoembolization and hepatic artery infusion chemotherapy in the treatment of primary liver cancer patients. Electron J Clin Gen Surg. 2025;13(01):21\u20134.","journal-title":"Electron J Clin Gen Surg"},{"issue":"08","key":"3980_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.13638\/j.issn.1671-4040.2024.08.001","volume":"24","author":"H Lu","year":"2024","unstructured":"Lu H, Wu JZ, Shen RC, et al. Observation on the clinical efficacy of combination therapy of lobaplatin and raltitrexed HAIC in the treatment of advanced liver cancer. J Practical Integr Traditional Western Med. 2024;24(08):1\u20135. https:\/\/doi.org\/10.13638\/j.issn.1671-4040.2024.08.001","journal-title":"J Practical Integr Traditional Western Med"},{"issue":"06","key":"3980_CR66","first-page":"331","volume":"27","author":"WS Liao","year":"2017","unstructured":"Liao WS, Zhang Y, Li JF, et al. Influence of two kinds of minimally invasive therapy on the survival rate, AFP and complications after operation of patients with primary hepatic carcinoma for moderate and advanced stage. J Integr Traditional Western Med Liver Disease. 2017;27(06):331\u20133.","journal-title":"J Integr Traditional Western Med Liver Disease"},{"issue":"01","key":"3980_CR67","first-page":"117","volume":"40","author":"MK Xu","year":"2018","unstructured":"Xu MK. Effects of two kinds of ablation schemes combined with TACE on short-term curative effects, survival rate and liver function of patients with primary hepatic carcinoma. Hebei Med J. 2018;40(01):117\u20139.","journal-title":"Hebei Med J"},{"key":"3980_CR68","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"3980_CR69","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301\u201314.","journal-title":"Lancet"},{"key":"3980_CR70","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19:151\u201372.","journal-title":"Nat Rev Clin Oncol"},{"key":"3980_CR71","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1148\/radiol.2021202289","volume":"298","author":"S Chen","year":"2021","unstructured":"Chen S, Peng Z, Zhang Y, Chen M, Li J, Guo R, et al. Lack of response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: abandon or repeat?? Radiology. 2021;298:680\u201392.","journal-title":"Radiology"},{"key":"3980_CR72","doi-asserted-by":"publisher","first-page":"5799","DOI":"10.1007\/s00330-022-08716-4","volume":"32","author":"D Xia","year":"2022","unstructured":"Xia D, Wang Q, Bai W, Wang E, Wang Z, Mu W, et al. Optimal time point of response assessment for predicting survival is associated with tumor burden in hepatocellular carcinoma receiving repeated transarterial chemoembolization. Eur Radiol. 2022;32:5799\u2013810.","journal-title":"Eur Radiol"},{"key":"3980_CR73","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/hepr.12568","volume":"46","author":"Y Wang","year":"2016","unstructured":"Wang Y, Deng T, Zeng L, Chen W. Efficacy and safety of radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a meta-analysis. Hepatol Res. 2016;46:58\u201371.","journal-title":"Hepatol Res"},{"key":"3980_CR74","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12957-021-02188-4","volume":"19","author":"C Jiang","year":"2021","unstructured":"Jiang C, Cheng G, Liao M, Huang J. Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis. World J Surg Onc. 2021;19:81.","journal-title":"World J Surg Onc"},{"key":"3980_CR75","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1177\/000313480206800920","volume":"68","author":"M Bloomston","year":"2002","unstructured":"Bloomston M, Binitie O, Fraiji E, Murr M, Zervos E, Goldin S, et al. Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am Surg. 2002;68:827\u201331.","journal-title":"Am Surg"},{"key":"3980_CR76","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.3760\/cma.j.issn.0366-6999.20111973","volume":"126","author":"H Guan","year":"2013","unstructured":"Guan H, Wang J, Yang M, Song L, Tong X, Zou Y. Changes in immunological function after treatment with transarterial chemoembolization plus radiofrequency ablation in hepatocellular carcinoma patients. Chin Med J (Engl). 2013;126:3651\u20135.","journal-title":"Chin Med J (Engl)"},{"key":"3980_CR77","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.jhep.2012.01.006","volume":"56","author":"J-W Park","year":"2012","unstructured":"Park J-W, Koh YH, Kim HB, Kim HY, An S, Choi J-I, et al. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol. 2012;56:1336\u201342.","journal-title":"J Hepatol"},{"key":"3980_CR78","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","volume":"4","author":"SM Yoon","year":"2018","unstructured":"Yoon SM, Ryoo B-Y, Lee SJ, Kim JH, Shin JH, An JH, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion. JAMA Oncol. 2018;4:661.","journal-title":"JAMA Oncol"},{"key":"3980_CR79","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/lt.23413","volume":"18","author":"SW Kwan","year":"2012","unstructured":"Kwan SW, Fidelman N, Ma E, Kerlan RK, Yao FY. Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation. Liver Transpl. 2012;18:727\u201336.","journal-title":"Liver Transpl"},{"key":"3980_CR80","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1002\/1097-0142(19940501)73:9<2259::AID-CNCR2820730905>3.0.CO;2-P","volume":"73","author":"T Higuchi","year":"1994","unstructured":"Higuchi T, Kikuchi M, Okazaki M. Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases. Cancer. 1994;73:2259\u201367.","journal-title":"Cancer"},{"key":"3980_CR81","doi-asserted-by":"publisher","first-page":"15101","DOI":"10.18632\/oncotarget.13145","volume":"8","author":"J Zhao","year":"2017","unstructured":"Zhao J, Zhang H, Wei L, Xie S, Suo Z. Comparing the long-term efficacy of standard and combined minimally invasive procedures for unresectable HCC: a mixed treatment comparison. Oncotarget. 2017;8:15101\u201313.","journal-title":"Oncotarget"},{"key":"3980_CR82","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1159\/000343875","volume":"3","author":"M Kudo","year":"2014","unstructured":"Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan. Liver Cancer. 2014;3:458\u201368.","journal-title":"Liver Cancer"},{"key":"3980_CR83","doi-asserted-by":"publisher","first-page":"102362","DOI":"10.1016\/j.coph.2023.102362","volume":"70","author":"M He","year":"2023","unstructured":"He M, Liu S, Lai Z, Du Z, Li Q, Xu L, et al. Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: applicability in Western countries. Curr Opin Pharmacol. 2023;70:102362.","journal-title":"Curr Opin Pharmacol"},{"key":"3980_CR84","doi-asserted-by":"publisher","first-page":"e32390","DOI":"10.1097\/MD.0000000000032390","volume":"101","author":"J Liu","year":"2022","unstructured":"Liu J, Zhang J, Wang Y, Shu G, Lou C, Du Z. HAIC versus TACE for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Med (Baltim). 2022;101:e32390.","journal-title":"Med (Baltim)"},{"key":"3980_CR85","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/jgh3.12573","volume":"5","author":"N Kawabe","year":"2021","unstructured":"Kawabe N, Hashimoto S, Nakano T, Nakaoka K, Fukui A, Yoshioka K. Transcatheter arterial infusion chemotherapy with cisplatin in combination with transcatheter arterial chemoembolization decreases intrahepatic distant recurrence of unresectable hepatocellular carcinoma. JGH Open. 2021;5:705\u201311.","journal-title":"JGH Open"},{"key":"3980_CR86","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ijsu.2020.09.031","volume":"83","author":"J Zheng","year":"2020","unstructured":"Zheng J, Cai J, Tao L, Kirih MA, Shen Z, Xu J, et al. Comparison on the efficacy and prognosis of different strategies for intrahepatic recurrent hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis. Int J Surg. 2020;83:196\u2013204.","journal-title":"Int J Surg"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03980-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-03980-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03980-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T11:03:54Z","timestamp":1747047834000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-03980-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3980"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-03980-2","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a meta-analysis. Chongqing Emergency Medical Center Research Ethics Committee has confirmed that no ethical approval is required. This is a meta-analysis. Informed consent is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"360"}}